Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Juno, Kite Stand By Their Products As Novartis's Shift Renews CAR-T Concerns

Executive Summary

Novartis's consolidation of its cell and gene therapy division into its corporate R&D operation has other leading CAR-T developers defending their therapeutic candidates against technical and manufacturing doubts.

Advertisement

Related Content

Killer Cures: Industry Heavyweights Make Their Presence Felt In Cell And Gene Therapy
CAR-T Update: Kite's Filing Coming Soon
Juno ROCKETs On Fast Clinical Hold Resolution
Three Deaths In Trial Mean Clinical Hold For Juno’s Lead CAR-T Therapy
Kite And Juno Threatened By Cellectis' Off-The-Shelf CAR-T Success
Companies Clearing Cell And Gene Therapy Manufacturing Hurdles

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097215

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel